NextCure Inc reports results for the quarter ended June 30 - Earnings Summary

• NextCure Inc NXTC.OQ reported a quarterly adjusted loss of $11.29​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-6.60. The mean expectation of two analysts for the quarter was for a loss of $4.61 per share. Wall Street expected results to range from $-4.68 to $-4.55 per share.

• Reported revenue was zero​; analysts expected zero.

• NextCure Inc's reported EPS for the quarter was a loss of $11.29​.

• The company reported a quarterly loss of $26.81 million.

• NextCure Inc shares had fallen by 6.5% this quarter and lost 44.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for NextCure Inc is $25.50, about 80% above its last closing price of $5.10

This summary was machine generated from LSEG data August 8 at 04:16 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)